

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

Date of Report: February 18, 2005

LIFELINE THERAPEUTICS, INC.

-----  
(Exact name of registrant as specified in its charter)

Colorado	000-30489	84-1097796
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6400 South Fiddler's Green Circle, Englewood, CO 80111

-----  
(New address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (720) 488-1711

YAAK RIVER RESOURCES, INC.

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act  
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act  
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the  
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the  
Exchange Act (17 CFR 240.13e-4(c)) Section 1 - Registrant's Business  
and Operations

Item 1.01 Entry into a Material Definitive Agreement

None

Item 1.02 Termination of a Material Definitive Agreement

None

Item 1.03 Bankruptcy or Receivership

None

Section 2 - Financial Information

Item 2.01 Completion of Acquisition or Disposition of Assets

None

Item 2.02 Results of Operations and Financial Condition

None

Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an  
Off-Balance Sheet Arrangement of a Registrant

None

Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation Under and Off-Balance Sheet Arrangement

None

Item 2.05 Costs Associated with Exit or Disposal Activities

None

Item 2.06 Material Impairments

None

Section 3 - Securities Trading Markets

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

None

### Item 3.02 - Unregistered Sales of Equity Securities

During the period from October 26, 2004, the date of the reorganization, through February 21, 2005, Lifeline Therapeutics has received \$2,545,000 in bridge loan financing from accredited investors. With the bridge loan financing, the accredited investors will be issued a number of warrants to purchase shares of Lifeline restricted common stock equal to the principal amount of their loan divided by \$2.00. The warrants will be exercisable for three years from the closing of the private placement at a price of \$2.00 per share. The bridge loan holders will be afforded the opportunity, in lieu of repayment, of exchanging their notes and accrued interest, at \$2.00 per share of common share, into a proposed private placement which is expected to consist of Units of common stock (at \$2.00 per share) and warrants exercisable for three years at \$2.50 per share.

The notes and warrants to be issued under bridge loan financing have not been and will not be registered under the Securities Act of 1933 (the "Act") or under the securities laws of any state. The notes and warrants will be "restricted securities" as defined in Rule 144 under the Act. These securities were offered pursuant to an exemption from registration provided by Sections 4(2) and 4(6) of the Act and Regulation D thereunder, and may not be reoffered or sold in the United States absent registration or an applicable exemption from the registration requirements. Lifeline has agreed to include the shares issuable upon conversion of the bridge notes and upon exercise of the warrants in a registration statement.

Lifeline has used the proceeds for working capital and to make payments to the Chemins Company for the manufacture of the Company's products.

### Item 3.03 Material Modification to Rights of Security Holders

None

## Section 4 - Matters Related to Accountants and Financial Statements

### Item 4.01 Changes in Registrant's Certifying Accountants

None

### Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

None.

## Section 5 - Corporate Governance and Management

### Item 5.01 Changes in Control of Registrant

None

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On February 14, 2005, the Board of Directors appointed Javier Baz as a member of the Board of Directors. Mr. Baz has held several executive positions with the Trust Company of the West, Los Angeles, California, most recently as Group Head and CIO - Private Client Services. Mr. Baz also founded, owned and operated Condor Securities, a broker dealer and asset management firm with over \$300 million under management. Mr. Baz previously held positions with Merrill Lynch as Managing Director, First Boston International, McKinsey & Co. and Citibank NA. Mr. Baz holds an undergraduate degree from the Wharton School of the University of Pennsylvania and an MBA from the Kellogg School, Northwestern University.

On February 21, 2005, Chris Micklatcher resigned as a director of Lifeline Therapeutics, Inc., its subsidiary Lifeline Nutraceuticals Corporation, and from all other positions he held in those corporations. Mr. Micklatcher expressly stated that there was no disagreement between him and either Lifeline Therapeutics, Inc. or Lifeline Nutraceuticals Corporation or its management on any matter relating to the operations of either corporation, their policies, or practices.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

None

Item 5.04 Temporary Suspension of Trading Under Registrant's Employee Benefit Plans

None

Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics.

None

Section 6 - [Reserved]

Section 7 - Regulation FD

Item 7.01 Regulation FD Disclosure

On February 18, 2005, Lifeline Therapeutics, Inc. became aware that on or about February 14, 2005, Vantage Point Investment Advisory, LLC published and distributed to its subscribers a newsletter (vol. 4, no. 3, March 2005). Lifeline Therapeutics, Inc. is hereby publicly alerting the marketplace that the information contained in that newsletter should not be relied upon. The marketplace should only rely on publicly filed and disclosed information from Lifeline Therapeutics, Inc.

Section 8 - Other Events

Item 8.01 Other Events

On February 15, 2005, Lifeline Therapeutics, Inc. filed a Form 12b-25 announcing that it was not timely filing its quarterly report on Form 10-QSB for the quarter ended December 31, 2004. Lifeline is continuing the work necessary to file this report as soon as possible.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

- (a) Financial Statements of Businesses Acquired.
- (b) Pro Forma financial information.
- (c) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 22, 2005

LIFELINE THERAPEUTICS, INC.

By: /s/ Daniel W. Streets

-----  
Daniel W. Streets, CFO/Secretary